Cardiol Therapeutics (CRDL) Retained Earnings (2020 - 2026)

Cardiol Therapeutics has reported Retained Earnings for 7 years, with the latest figure at -$163.3 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 24.91% year-over-year to -$163.3 million; the trailing twelve-month figure through Mar 2026 stood at -$163.3 million (down 24.91% YoY), and the FY2025 full-year result was -$152.8 million, down 19.07% from the prior year.
• Retained Earnings for Q1 2026 stood at -$163.3 million, down from -$152.8 million in the prior quarter.
• The five-year high for Retained Earnings was -$73.0 million in Q1 2022, with the low at -$163.3 million in Q1 2026.
• Historically, Retained Earnings has averaged -$113.4 million across 5 years, with a median of -$112.6 million in 2024.
• Annual changes were most pronounced in 2022 — Retained Earnings plunged 41.66% — and 2025, when it decreased 16.05%.
• Cardiol Therapeutics' Retained Earnings stood at -$84.3 million in 2022, then slipped by 24.21% to -$104.7 million in 2023, then slipped by 22.53% to -$128.3 million in 2024, then slipped by 19.07% to -$152.8 million in 2025, then slipped by 6.85% to -$163.3 million in 2026.
• The last three Retained Earnings figures came in at -$163.3 million (Q1 2026), -$152.8 million (Q4 2025), and -$149.6 million (Q3 2025), per Business Quant data.